Novartis AG





Real-time Estimate Cboe Europe 11:02:26 2023-11-28 am EST Intraday chart for Novartis AG 5-day change 1st Jan Change
85.36 CHF -0.72% +0.40% +2.18%
This content is reserved for premium subscribers
To unlock exclusive news, subscribe to Premium!
Maximize your earnings and get expert advice
to become a successful investor with our premium subscription
Already a member/customer? Log In
European Midday Briefing : Stocks Struggle Again as November Rally Continues to Stall DJ
NOVARTIS AG : Gets a Neutral rating from UBS ZD
NOVARTIS : price target maintained by Oddo BHF CF
NOVARTIS AG : Jefferies reaffirms its Buy rating ZD
Novartis Touts R&D Pipeline Progress, Upgraded Midterm Targets as Pure-play Medicines Company MT
Novartis lifts sales growth target to 5% per year through 2027 RE
Novartis Raises Mid-Term Sales Growth Targets DJ
Novartis Raises Mid-term Targets After Emerging as Pure-play Medicines Company MT
Novartis: medium-term growth target raised CF
Huluwa Pharma Registers Hypertension Drug MT
Novartis aims for 5% annual sales growth through 2027 RE
Novartis Closes Sale of Cell, Gene Therapy Unit to Seqens MT
Jefferies: Investor Interest Shifts from Daiichi Sankyo to Chugai and Otsuka Holdings MT
NOVARTIS AG : Receives a Buy rating from Deutsche Bank ZD
Novartis Recalls Two Lots of Sandimmune Cyclosporine Oral Solution Over Incorrect Dosing Concerns MT
US Jobless Data Sends Swiss Equities Higher Ahead of Thanksgiving Break MT
BeiGene to buy global rights to Ensem's experimental cancer therapy RE
Novartis: presents data from over 100 trials CF
Bayer stops blood thinner drug trial due to lack of effect, in major setback RE
Alcon slightly misses Q3 net sales, narrows full-year outlook RE
Genscript Subsidiary Legend Biotech Grants Novartis License to Develop Anti-Cancer Drug MT
Legend Biotech Gets $100 Million From Novartis in Global License Agreement for CAR-T Therapies MT
Transcript : Novartis AG - Special Call CI
Legend Biotech Subsidiary in License Agreement With Novartis DJ
Starpharma Names CEO MT
Chart Novartis AG
More charts
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (81.7%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal disorders, cancers, central nervous system disorders, hormone imbalances, etc.; - generic drugs (18.3%; Sandoz). Net sales are distributed geographically as follows: Europe (36.5%), the United States (34.9%), Asia/Africa/Australasia (20.9%), Canada and Latin America (7.7%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
More Ratings
Mean consensus
Number of Analysts
Last Close Price
Average target price
Spread / Average Target
1st Jan change Capi. (M$)
+2.18% 201 B $
+62.37% 532 B $
+47.10% 464 B $
-14.30% 364 B $
-13.84% 246 B $
-18.80% 216 B $
-11.56% 195 B $
-41.63% 170 B $
+1.44% 141 B $
-4.20% 119 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Novartis AG - Swiss Exchange
  4. News Novartis AG
  5. Novartis : Healthy operating momentum pushes expectations higher
-40% off Black Friday : Our subscriptions help you unlock the best investment opportunities.
Enjoy this offer